PTK7 dpADC — IND submission
2026
IND filing anticipated in 2026Source filing
STRO biotech catalysts & pipeline
SUTRO BIOPHARMA INC · Data as of 2026-10-25
Upcoming catalysts
STRO-006 — IND submission
H2 2026
IND enabling activities are underway for STRO-006 that could potentially support an IND filing in connection with this program in the second half of 2026.Source filing
STRO-227 — IND submission
late 2026
We have initiated certain chemistry, manufacturing and controls, or CMC, related activities for the PTK7-targeting dual-payload ADC and anticipate submitting an IND in connection with this program in late 2026.Source filing
dual-payload ADC — IND submission
2027
Sutro's wholly owned dual-payload ADC program remains on track, with an IND submission targeted for 2027.Source filing
STRO-004 — Interim data
H1 2027
The next STR IV E-01 study update is targeted for the first half of 2027.Source filing
STRO-006 — Initial data
H2 2027
Sutro Biopharma, Inc. — STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 —Source filing
STRO-004 — IND submission
Late 2027
We plan to file three INDs by the end of 2027, including for STRO-004 and for STRO-006.Source filing